体外生命支持后植入HeartMate 3患者的结局:代表体外生命支持后持久机械循环支持研究组
该多中心注册研究分析了2016年1月至2022年4月14个中心337例体外生命支持后桥接持久机械循环支持的患者,其中140例植入HeartMate 3。HeartMate 3组术后卒中(16% vs 28%,P=.01)和泵血栓(3% vs 8%,P=.02)显著低于其他泵组,30天、1年、3年生存率分别为87%、73%、65%。
要点
- 体外生命支持后桥接HeartMate 3的患者30天、1年、3年生存率分别为87%、73%、65%。
- HeartMate 3组术后卒中发生率16%,显著低于其他泵组的28%(P=.01)。
- HeartMate 3组泵血栓发生率3%,显著低于其他泵组的8%(P=.02)。
核心结论
- 在这一危重患者群体中,体外生命支持后过渡至HeartMate 3的患者生存率被认为可接受,且优于体外生命支持桥接至其他类型持久机械循环支持系统时观察到的生存率。
研究设计与样本
- 多中心注册研究,收集2016年1月至2022年4月14个中心接受HeartMate 3植入的患者数据。
- 纳入标准为HeartMate 3植入前接受体外生命支持的患者,共140例植入HeartMate 3。
- 研究期间共有337例患者从体外生命支持桥接至持久机械循环支持系统,其他泵包括170例HeartWare HVAD(86%)、14例HeartMate II(7%)和13例(7%)其他泵。
主要发现
- 主要术后并发症包括需要临时右心室辅助装置的右心衰竭,发生于60例患者(47%)。
- HeartMate 3组术后卒中发生率为16%,其他泵组为28%,差异显著(P=.01)。
- HeartMate 3组泵血栓发生率为3%,其他泵组为8%,差异显著(P=.02)。
- HeartMate 3组30天、1年和3年生存率分别为87%、73%和65%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The Durable Mechanical Circulatory Support System After Extracorporeal Life Support registry is a multicenter registry of patients who were bridged from extracorporeal life support to a durable mechanical circulatory support system. Although numerous studies have highlighted the favorable outcomes after implantation of the HeartMate 3 (Abbott), the objective of our study is to examine the outcomes of patients who received HeartMate 3 support after extracorporeal life support. METHODS: Data of patients undergoing HeartMate 3 implantation from January 2016 to April 2022 at 14 centers were collected and evaluated. Inclusion criteria were patients with extracorporeal life support before HeartMate 3 implantation. The outcome was reported and compared with patients receiving other types of pumps. RESULTS: A total of 337 patients were bridged to durable mechanical circulatory support system after extracorporeal life support in the study period. Of those patients, 140 were supported with the HeartMate 3. The other types of pumps included 170 HeartWare HVADs (Medtronic) (86%), 14 HeartMate II devices (7%), and 13 (7%) other pumps (7%). Major postoperative complications included right heart failure requiring temporary right ventricular assist device in 60 patients (47%). Significantly lower postoperative stroke (16% vs 28%, P = .01) and pump thrombosis (3% vs 8%, P = .02) rates were observed in the patients receiving the HeartMate 3. The 30-day, 1-year, and 3-year survivals in patients receiving the HeartMate 3 were 87%, 73%, and 65%, respectively. CONCLUSIONS: In this critically ill patient population, the survivals of patients who were transitioned to the HeartMate 3 are deemed acceptable and superior to those observed when extracorporeal life support was bridged to other types of durable mechanical circulatory support systems.
引用
- Saeed D, Stark C, Otto W, et al. Outcome of patients supported with the HeartMate 3 after extracorporeal life support: On behalf of the Durable Mechanical Circulatory Support After Extracorporeal Life Support Study Group. J Thorac Cardiovasc Surg. 2023. PMID: 37689237. doi:10.1016/j.jtcvs.2023.08.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。